The first, called nirmatrelvir, blocks the activity of an enzyme the COVID-19 virus needs to copy itself, also called repl ...

FDA recalls Gilead's COVID drug Veklury due to glass particles as 21 states show "very high" virus levels in wastewater ...

Health authorities have said that stockpiled Tamiflu should work well against H5N1. Some experts question that bet.

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 ...

MDA5 is a critical cytoplasmic RNA sensor capable of triggering type I interferon pathways. This study shows that the E3 ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

Health Canada says it's still reviewing data on an antiviral COVID-19 drug that ... available" from pharmaceutical company Merck on their drug molnupiravir, considered the first pill to ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

JPI-289 is under clinical development by Jeil Pharmaceutical and currently in Phase II for Myocardial Infarction.

Summit Therapeutics (NASDAQ:SMMT) shares soar 51% after its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49% compared to Merck’s (NYSE ...